$190.7 Million

Nuvalent, Inc.

Initial Public Offering

Bookrunner, July 2021

Nuvalent, Inc. (the “Company”) is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. The Company is advancing a pipeline of novel product candidates with parallel lead programs in ROS1-positive and ALK-positive cancers, along with multiple discovery-stage research programs. The Company’s lead asset, NVL-520, is a brain-penetrant ROS1-selective inhibitor, designed to inhibit wild-type ROS1 fusions and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors. The Company’s second lead asset, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to inhibit wild-type ALK fusions and remain active in the presence of mutations conferring resistance to first-, second-, and third-generation ALK inhibitors.

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$116.3 Million

Initial Public Offering

Bookrunner

View Details
Nov 2021
$500.3 Million

Initial Public Offering

Bookrunner

View Details